reports
- Jean-François Granjon
- Louis Boujard
- CFA
EVT EVOTEC SE
PHA PHARMAGEST INTERACTIVE SA
ALDEL DELFINGEN INDUSTRY SA
OERL OC OERLIKON CORPORATION AG
VRAP VRANKEN-POMMERY MONOPOLE SA
NOEJ NORMA GROUP SE
POS PORR AG
ADN1 ADESSO AG
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
CSM CORBION NV
WPL WIRTUALNA POLSKA HOLDING SA
DMP DERMAPHARM HOLDING SE
ATRY ATRYS HEALTH
S30 SOLUTIONS 30 SE
KTA KNAUS TABBERT
LHYFE LHYFE S.A.
CO CASINO GUICHARD-PERRACHON
- Jean-François Granjon
- Louis Boujard
- CFA
EVT EVOTEC SE
PHA PHARMAGEST INTERACTIVE SA
ALDEL DELFINGEN INDUSTRY SA
OERL OC OERLIKON CORPORATION AG
VRAP VRANKEN-POMMERY MONOPOLE SA
VETO VETOQUINOL SA
NOEJ NORMA GROUP SE
POS PORR AG
ADN1 ADESSO AG
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
CSM CORBION NV
WPL WIRTUALNA POLSKA HOLDING SA
DMP DERMAPHARM HOLDING SE
ATRY ATRYS HEALTH
S30 SOLUTIONS 30 SE
KTA KNAUS TABBERT
LHYFE LHYFE S.A.
CO CASINO GUICHARD-PERRACHON
- Robert Jan Vos
- Reg Watson
- CFA
Corbion/Goldilocks scenario extends/HOLD
Since our 12-month target price upgrade to €18.60 and change in recommendation from Sell to HOLD on 17 November 2025, Corbion has delivered its Capital Markets Day and full year results. Corbion confirmed at its 2025 results that the company had taken advantage of the low sugar price to hedge all its exposure for 2026 and 75% for 2027. This extends the Goldilocks scenario of lower costs and higher revenues from 2026 into 2027 and supports approximately half of the company's guided adj. EBITDA ma...
IBA – ACQUISITION OF OWN SHARES
IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 30th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 2026...
IBA – ACQUISITION D’ACTIONS PROPRES
IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à parti...
- ING Helpdesk
Benelux Morning Notes
AEGON: merger of Corebridge and Equitable, implications for Transamerica. Flow Traders: Equity strong as crypto fades. IBA: Net debt above, FY26 REBIT guidance on the low side, 2H25 REBIT a bit below. Sofina: Final NAV 2% above preliminary results. Zabka: Peer Dino Polska FY25 results
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Wim Hoste
- Wim Hoste
IBA FIRST LOOK: FY25 REBIT +58%, FY26 guidance of at least 17% growth
IBA reported solid FY25 results, with revenues up 24% to € 620m (kbcse: € 614m), driven by an accelerated backlog conversion and good order intake. However, gross profit margins still contracted by 150bps to 32.2%, driven by negative mix effects from legacy lower margin PT contracts. Nevertheless, as this was already anticipated, the FY25 REBIT of € 27.4m came in above the guidance of at least € 25m and was in line with our forecast. The 2026 guidance calls for a REBIT of at least € 32m (kbcse: ...
IBA réalise des résultats solides pour l'exercice 2025, avec une exécu...
IBA réalise des résultats solides pour l'exercice 2025, avec une exécution maîtrisée dans tous les segments pour lire l'intégralité du communiqué de presse des résultats annuels 2025 Louvain-La-Neuve, Belgique, 27 mars 2026 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour l'exercice 2025, avec une exécution maîtrisée dans tous les segments d'activité. La forte dynamique commerciale, notamment en Proton Therapy, se traduit par une prise de commandes et un carnet de commandes record. Conforme aux objectifs annoncés, l'année a été marquée par la poursu...
IBA delivers strong FY 2025 results with solid execution in all segmen...
IBA delivers strong FY 2025 results with solid execution in all segments Read the entire full-year 2025 results press release Louvain-la-Neuve, Belgium, 27 March 2026 - IBA (Ion Beam Applications S.A.), today announces its consolidated results of 2025 financial year, with strong execution across the businesses. Robust commercial momentum, notably in Proton Therapy, resulted in a historic order intake and a new all-time high backlog. Delivered in line with guidance, the year marks continued progress in the execution of IBA’s strategic roadmap to the benefit of all its stakeholders. R...
- Lynn Hautekeete
- Wim Lewi
WEB WAREHOUSES ESTATES BELGIUM S.C.A.
LEAS LEASINVEST REAL ESTATE SCA
IMMO COMPAGNIE IMMOBILIERE DE BELGIQUE SA
RET RETAIL ESTATES NV
ELI ELIA GROUP SA/NV
MONT MONTEA SCA
AED AEDIFICA SA
QRF QRF COMM
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
ASC ASCENCIO SCA
ARG ARGAN SA
VGP VGP NV
TINC TINC COMM. VA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
HOMI HOME INVEST BELGIUM
SHUR SHURGARD SELF STORAGE LIMITED
ENRGY ENERGYVISION
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Hoste
IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle...
IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy The first wireless ionization chamber array for particle therapy PSQA delivers fast, reliable verification for proton and carbon ion treatments, supporting emerging techniques such as FLASH and ARC radiotherapy. Louvain-la-Neuve, Belgium, 21 March 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global provider of dosimetry and quality assurance (QA) solutions, announces the launch of myQA MatriXX AiR, a high resolution, wireless 2D ionization chamber...
L'IBA lance myQA MatriXX AiR et fait évoluer l'assurance qualité spéci...
L'IBA lance myQA MatriXX AiR et fait évoluer l'assurance qualité spécifique des patients en thérapie par particules La première gamme de chambres d'ionisation sans fil pour la thérapie par particules, PSQA, fournissant une vérification rapide et fiable des traitements par protons et ions carbone, et adaptée aux techniques émergentes telles que la radiothérapie FLASH et ARC. Louvain-la-Neuve, Belgique, 21 mars 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial de la technologie d'accélérateurs de particules et fournisseur mondial de solutions de dosimétrie et d'assurance qu...
- ING Helpdesk
- Hilde Van Boxstael
- Livio Luyten
- Wim Hoste
- Wim Lewi
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in...
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S. Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions1. The systems will be installed at select RLS Radiopharmacies (RLS) sites in...
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de pr...
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis Louvain‑la‑Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de radiopharmaceutiques, annonce la signature d’un contrat avec Telix Pharmaceuticals Limited (Telix ; ASX : TLX, NASDAQ : TLX), entreprise d’oncologie de précision, pour une première commande de quatre cyclotrons Cyclone® KIUBE aux conditions standards d’IBA1. Les systèmes seront installés...
- Lynn Hautekeete
- Wim Lewi
LEAS LEASINVEST REAL ESTATE SCA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
IMMO COMPAGNIE IMMOBILIERE DE BELGIQUE SA
RET RETAIL ESTATES NV
ELI ELIA GROUP SA/NV
MONT MONTEA SCA
AED AEDIFICA SA
QRF QRF COMM
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
ASC ASCENCIO SCA
ARG ARGAN SA
VGP VGP NV
TINC TINC COMM. VA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
HOMI HOME INVEST BELGIUM
SHUR SHURGARD SELF STORAGE LIMITED
ENRGY ENERGYVISION
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.